脳脊髄液（CSF）管理の世界市場予測（2022年～2027年）

世界の脳脊髄液（CSF）管理の市場規模は、2020年の7億537万3,000米ドルから、2027年には9億6,184万5,000米ドルに達し、予測期間中のCAGRで4.53％の成長が予測されています。

同市場は、新興国における複数の神経治療設備の発展や、安価な治療を受けられる機会の増加を受けて拡大しています。神経疾患の有病率上昇、低侵襲手術の高い需要、老年人口の増加、可処分所得の増加、医療インフラの進歩、先進機器の開発などは、脳脊髄液管理機器市場の成長に寄与する要因となっています。

当レポートでは、世界の脳脊髄液（CSF）管理市場を調査しており、市場の概要、市場の促進要因や抑制要因、製品タイプ・エンドユーザー・業界・地域別の分析、競合情勢、企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション

第2章 調査手法

• 調査データ
• 前提条件

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • サプライヤーの交渉力
  • バイヤーの交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 業界における競合情勢
• 業界のバリューチェーン分析

第5章 世界の脳脊髄液（CSF）管理市場：製品タイプ別

• イントロダクション
• CSFシャント
• 体外ドレナージシステム

第6章 世界の脳脊髄液（CSF）管理市場：エンドユーザー別

• イントロダクション
• 小児
• 成人
• 高齢者

第7章 世界の脳脊髄液（CSF）管理市場：業界別

• イントロダクション
• 病院
• クリニック
• その他

第8章 世界の脳脊髄液（CSF）管理市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • その他
• 中東・アフリカ
  • サウジアラビア
  • イスラエル
  • その他
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • インドネシア
  • タイ
  • 台湾
  • その他

第9章 競合環境と分析

• 主要企業と戦略分析
• 新興企業と市場の有利性
• 合併、買収、合意、およびコラボレーション
• ベンダー競争力マトリックス

第10章 企業プロファイル

• Medtronic
• Integra
• DePuy Synthes
• B.Braun
• Spiegelberg GmbH & Co. KG
• Sophysa (A subsidiary of tkb group)
• Natus Medical Incorporated
• Argi Grup
• Moller Medical GMBH
• Delta Surgical
• Wellong Instruments Co., Ltd.

The global cerebrospinal fluid (CSF) management market is projected to grow at a CAGR of 4.53% during the forecast period to reach US$961.845 million by 2027, from US$705.373 million in 2020. Cerebrospinal fluid is a bodily fuel found in the brain and spinal cord that protects the brain mechanically and immunologically. Various management devices, such as CSF drainage systems and CSF shunts, are used to control the flow of CSF away from the ventricles in the body, preventing inappropriate CSF accumulation and hydrocephalus.

The expansion of the market is being aided by the development of several neurohospitals in emerging countries, as well as increased chances for cheap treatment. The growing prevalence of neurological disorders, the high demand for minimally invasive surgeries, the growing geriatric population, rising disposable incomes, the advancement of healthcare infrastructure, and the development of advanced devices are among the contributing factors to the growth of the cerebrospinal fluid management devices market. Furthermore, the treatment of the disease demands advanced technology and infrastructure, both of which are commonly found in hospitals. Hospitals are treating various neurovascular illnesses as a result of the introduction of new products and technical improvements, that will give lucrative market growth prospects throughout the projected period. According to the National Institute of Neurological Disorders and Stroke, one to two out of every 1000 babies worldwide are born with hydrocephalus. As a result, the prevalence of hydrocephalus is expected to rise in the future, given the total number of babies each year.

One of the most significant constraints on global business is the scarcity of qualified neurosurgeons. Globally, there is a major scarcity of qualified specialists. The existing number of neurosurgeons is insufficient to meet the demand for quality healthcare in a rapidly rising senior population. Rising problems connected with CSF shunts and sensor-related infections are two major issues that are predicted to limit the worldwide cerebrospinal fluid management market's growth in the projected period. Apart from that, the market's growth is hampered by the high cost of devices and the infections generated by CSF shunts.

Key Developments

CereVasc closed its Series A round of USD 43.9 million in June 2020, led by Perceptive Xontogeny Venture Fund and ATON Partners, focusing on the E-shunt system's clinical study as well as follow-up clinical research to support regulatory approvals. Biocept announced the commercial launch of the CNSide cerebrospinal fluid assay in April 2021 to meet the needs of patients with advanced brain cancer. Anuncia announced that its ReFlow system for CSF management obtained FDA breakthrough device designation in March 2020.

By product type, the global cerebrospinal fluid (CSF) management market can be segmented into external drainage systems and shunts. Shunts are expected to dominate the cerebrospinal fluid (CSF) management industry in the next few years owing to the rising number of shunting procedures conducted worldwide, as well as the increasing number of revision shunt surgeries due to shunt malfunction and infection, which can be linked to this product segment's substantial market share. The advantages associated with these shunts over traditional shunts, such as the reduced likelihood of revision surgery and a shorter average length of hospital stay, are fuelling the expansion of this market.

By end-users, the global cerebrospinal fluid (CSF) management market can be segmented into an adult, pediatric, and geriatric. During the forecast period, the paediatric category is estimated to account for a considerable revenue share of the market. The increased prevalence of congenital hydrocephalus and the increasing number of shunting procedures performed in the paediatric population are responsible for the high revenue growth. Furthermore, the geriatric segment is anticipated to have significant market growth due to the rising burden of neurological disorders and an ageing population.

By industry, the global cerebrospinal fluid (CSF) management market can be segmented into hospitals, clinics, and others. Due to the large number of hospital cases linked to CSF management in the ageing population, the hospital segment is anticipated to account for a sizable market share and is expected to expand at the fastest rate over the projection period.

By geography, the global cerebrospinal fluid (CSF) management market can be segmented into the Asia Pacific, North America, the Middle East and Africa, South America, and Europe. Over the projected period, the Asia Pacific region is expected to grow at the highest rate. The developing medical tourism in India and other Asia Pacific countries, the rising prevalence of congenital hydrocephalus in China, and the growing geriatric population in various nations in the area are all factors driving revenue growth in this regional market.

Key Developments:

• Alcyone Lifesciences has received the approval of the U.S. Food and Drug Administration to launch the Alivio Ventricular Catheter & Flusher System (Alivio System) for the treatment of hydrocephalus.
• Biocept announced the commercial launch of the CNSide cerebrospinal fluid assay in April 2021 to meet the needs of patients with advanced brain cancer. Anuncia announced that its ReFlow system for CSF management obtained FDA breakthrough device designation in March 2020.

COVID-19 Insights

The COVID-19 epidemic impacted the global cerebrospinal fluid (CSF) management market significantly. The COVID-19 epidemic wreaked havoc on the hospital system by forcing the admission of large numbers of critically ill patients. COVID-19 treatment became a priority as a result of this delay in other healthcare deliveries. In addition, the installation of lockdowns hampered research and awareness programs. However, since the viral outbreak, the situation has greatly improved. The healthcare industry has seen a surge in investment with global recognition of the importance of R & D in healthcare and the development of breakthrough products As a result of increased investment activity, the CSF management industry is likely to grow rapidly.

Market Segmentation:

• By Product Type

CSF Shunts

External Drainage Systems

• By End-Users

Pediatric

Adult

Geriatric

• By Industry

Hospitals

Clinics

Others

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Middle East and Africa

• Saudi Arabia
• Israel
• Others

Asia Pacific

• China
• Japan
• India
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Overview
• 1.2. Covid-19 Scenario
• 1.3. Market Definition
• 1.4. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Function
• 4.4. Function Value Chain Analysis

5. GLOBAL CEREBROSPINAL FLUID (CSF) MANAGEMENT MARKET, BY PRODUCT TYPE 

• 5.1. Introduction
• 5.2. CSF Shunts
• 5.3. External Drainage Systems

6. GLOBAL CEREBROSPINAL FLUID (CSF) MANAGEMENT MARKET, BY END-USERS 

• 6.1. Introduction
• 6.2. Pediatric
• 6.3. Adult
• 6.4. Geriatric

7. GLOBAL CEREBROSPINAL FLUID (CSF) MANAGEMENT MARKET, BY INDUSTRY

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Clinics
• 7.4. Others

8. GLOBAL CEREBROSPINAL FLUID (CSF) MANAGEMENT MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom 
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Italy
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. Israel
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Taiwan 
  • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrative
• 9.3. Mergers, Acquisition, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES 

• 10.1. Medtronic
• 10.2. Integra LifeSciences
• 10.3. Johnson & Johnson MEDTECH
• 10.4. B. Braun Melsungen AG
• 10.5. Spiegelberg GmbH & Co. KG (Acquired by SHS Medizintechnik Holding GmbH)
• 10.6. Sophysa (A subsidiary of tkb group), 
• 10.7. Natus Medical Incorporated (Acquired by ArchiMed Group)
• 10.8. Argi Grup
• 10.9. Moller Medical GMBH 
• 10.10. Delta Surgical
• 10.11. Wellong Instruments Co., Ltd.